Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 73


Evidence That a Neutrophil-Keratinocyte Crosstalk Is an Early Target of IL-17A Inhibition in Psoriasis.

Reich K, Papp KA, Matheson RT, Tu JH, Bissonnette R, Bourcier M, Gratton D, Kunynetz RA, Poulin Y, Rosoph LA, Stingl G, Bauer WM, Salter JM, Falk TM, Blödorn-Schlicht NA, Hueber W, Sommer U, Schumacher MM, Peters T, Kriehuber E, Lee DM, Wieczorek GA, Kolbinger F, Bleul CC.

Exp Dermatol. 2015 Apr 1. doi: 10.1111/exd.12710. [Epub ahead of print]


Improvements in patient-reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE.

Papp KA, Barber K, Bissonnette R, Bourcier M, Lynde CW, Poulin Y, Shelton J, Garces K, Toole J, Poulin-Costello M.

J Eur Acad Dermatol Venereol. 2015 Jan 21. doi: 10.1111/jdv.12934. [Epub ahead of print]


A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE).

Papp KA, Barber K, Bissonnette R, Bourcier M, Lynde CW, Poulin Y, Shelton J, Toole J, Vieira A, Poulin-Costello M.

J Eur Acad Dermatol Venereol. 2015 Feb;29(2):361-6. doi: 10.1111/jdv.12555. Epub 2014 Jul 1.


Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions.

Menter A, Papp KA, Tan H, Tyring S, Wolk R, Buonanno M.

J Drugs Dermatol. 2014 Mar;13(3):252-6.


Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation.

Szarewski A, Skinner SR, Garland SM, Romanowski B, Schwarz TF, Apter D, Chow SN, Paavonen J, Del Rosario-Raymundo MR, Teixeira JC, De Carvalho NS, Castro-Sanchez M, Castellsagué X, Poppe WA, De Sutter P, Huh W, Chatterjee A, Tjalma WA, Ackerman RT, Martens M, Papp KA, Bajo-Arenas J, Harper DM, Torné A, David MP, Struyf F, Lehtinen M, Dubin G.

J Infect Dis. 2013 Nov 1;208(9):1391-6. doi: 10.1093/infdis/jit360.


Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use.

Brodmerkel C, Wadman E, Langley RG, Papp KA, Bourcier M, Poulin Y, Ho V, Guenther L, Kunynetz R, Nigen S, Vender R, Wasel N, Hsu MC, Szapary P.

J Drugs Dermatol. 2013 Oct;12(10):1122-9.


Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics.

Mease PJ, Gladman DD, Papp KA, Khraishi MM, Thaçi D, Behrens F, Northington R, Fuiman J, Bananis E, Boggs R, Alvarez D.

J Am Acad Dermatol. 2013 Nov;69(5):729-35. doi: 10.1016/j.jaad.2013.07.023. Epub 2013 Aug 24.


Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study.

Papp KA, Sundaram M, Bao Y, Williams DA, Gu Y, Signorovitch JE, Wang Y, Valdes JM, Mulani PM.

J Eur Acad Dermatol Venereol. 2014 Jun;28(6):790-8. doi: 10.1111/jdv.12177. Epub 2013 May 17.


Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.

Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, Chan D, Hsu MC, Ho V, Ghislain PD, Strober B, Reich K; PHOENIX 1 Investigators; PHOENIX 2 Investigators; ACCEPT Investigators.

Br J Dermatol. 2013 Apr;168(4):844-54. doi: 10.1111/bjd.12214.


Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study.

Kimball AB, Papp KA, Wasfi Y, Chan D, Bissonnette R, Sofen H, Yeilding N, Li S, Szapary P, Gordon KB; PHOENIX 1 Investigators.

J Eur Acad Dermatol Venereol. 2013 Dec;27(12):1535-45. doi: 10.1111/jdv.12046. Epub 2012 Dec 20.


PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents.

Papp KA, Strober B, Augustin M, Calabro S, Londhe A, Chevrier M; PSOLAR investigators and Steering Committee.

J Drugs Dermatol. 2012 Oct;11(10):1210-7.


Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.

Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, Haemmerle S, Thurston HJ, Papavassilis C, Richards HB.

Br J Dermatol. 2013 Feb;168(2):412-21. doi: 10.1111/bjd.12110. Epub 2013 Jan 18.


Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study.

Papp KA, Kaufmann R, Thaçi D, Hu C, Sutherland D, Rohane P.

J Eur Acad Dermatol Venereol. 2013 Mar;27(3):e376-83. doi: 10.1111/j.1468-3083.2012.04716.x. Epub 2012 Oct 3.


Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.

Papp KA, Menter A, Strober B, Langley RG, Buonanno M, Wolk R, Gupta P, Krishnaswami S, Tan H, Harness JA.

Br J Dermatol. 2012 Sep;167(3):668-77. doi: 10.1111/j.1365-2133.2012.11168.x.


Biologic therapy in psoriasis: perspectives on associated risks and patient management.

Papp KA, Dekoven J, Parsons L, Pirzada S, Robern M, Robertson L, Tan JK.

J Cutan Med Surg. 2012 May-Jun;16(3):153-68. Review.


Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial.

Papp KA, Reid C, Foley P, Sinclair R, Salinger DH, Williams G, Dong H, Krueger JG, Russell CB, Martin DA.

J Invest Dermatol. 2012 Oct;132(10):2466-9. doi: 10.1038/jid.2012.163. Epub 2012 May 24. No abstract available.


A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis.

Gottlieb AB, Langley RG, Strober BE, Papp KA, Klekotka P, Creamer K, Thompson EH, Hooper M, Kricorian G.

Br J Dermatol. 2012 Sep;167(3):649-57. doi: 10.1111/j.1365-2133.2012.11015.x.


Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.

Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, Aras G, Li J, Russell CB, Thompson EH, Baumgartner S.

N Engl J Med. 2012 Mar 29;366(13):1181-9. doi: 10.1056/NEJMoa1109017.


An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up.

Reich K, Papp KA, Griffiths CE, Szapary PO, Yeilding N, Wasfi Y, Ott E, Hsu MC, Lebwohl M, Gordon KB; PHOENIX 1, PHOENIX 2, and ACCEPT investigators.

J Drugs Dermatol. 2012 Mar;11(3):300-12.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk